companyName

feedTypes

includeDividend

includeEstimates

includeExtensive

includeOverview

includeOwnership

includeShortSelling

researchId

CompanyPage_Query

companySlug

CompanyMetaData

Company_query

company

name

description

pageUrl

websiteUrl

logoUrl

squareLogoUrl

defaultInstrument

companyInsref

viewerIsFollowing

followersCount

isCorporateCustomer

hasVaraConsensus

hasDividendHistory

sector

regions

extensiveResearchExists

hasPinpointData

topOwners

insiderTransactions

varaConsensus

isPayingCustomerOf

isFormerCustomerOf

feedContent

SenzaGen

Correction: SenzaGen’s interim report January–June 2026 | Continued strong development in Q2 2026 – 13% growth with positive cash flow

SenzaGen’s interim report January–June 2026 | Continued strong development in Q2 2026 – 13% growth with positive cash flow

Invitation to the presentation of SenzaGen's January-June 2026 interim report

SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million

EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential

Report from AGM of SenzaGen AB on 12 May 2026

SenzaGen’s interim report January–March 2026 | 10% sales growth alongside increased attention to non-animal methods

Invitation to the presentation of SenzaGen's January-March 2026 interim report

SenzaGen’s Annual Report 2025 published

SenzaGen’s subsidiary receives strategically important order

NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ)

SenzaGen wins new global cosmetics group as customer

SenzaGen to present strong GARD®skin data at the world’s largest toxicology conference together with leading industry partners

Growing interest in non-animal respiratory allergy testing – GARD®air data presented by industry leaders

SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group

SenzaGen’s Year-End Report 2025 | SenzaGen closes the year with continued strong GARD® sales

Invitation to the presentation of SenzaGen's year-end report 2025

SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader

SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan

BioStock: Video from SenzaGen's presentation at BioStock Life Science Summit 2025

UK signals shift to non-animal testing – new opportunities for SenzaGen

SenzaGen secures order worth SEK 2.5 million from leading global tech company

SenzaGen presents growth plan and strategic priorities at Capital Markets Day

SenzaGen’s interim report January–September 2025 | Growth and break-even in Q3

Invitation to the presentation of SenzaGen's Q3 2025 interim report

First North Stockholm

Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund. 

Societe Generale

Caceis Bank, Germany Branch, W8IMY

Yksityisyysasetukset

SenzaGen

Sijoittajien näkemys

Sijoittajien ennusteet

SenzaGen

Sijoittajien näkemys

Sijoittajien ennusteet